FibroGen, Inc.

NASDAQ:FGEN

7.18 (USD) • At close July 29, 2025
Bedrijfsnaam FibroGen, Inc.
Symbool FGEN
Munteenheid USD
Prijs 7.18
Beurswaarde 29,019,837
Dividendpercentage 0%
52-weken bereik 4.5 - 29
Industrie Biotechnology
Sector Healthcare
CEO Mr. Thane Wettig
Website https://www.fibrogen.com

An error occurred while fetching data.

Over FibroGen, Inc.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the

Vergelijkbare Aandelen

Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

6.37 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.097 USD

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

1.55 USD

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

8.1 USD

Avid Bioservices, Inc. logo

Avid Bioservices, Inc.

CDMO

12.49 USD

Phibro Animal Health Corporation logo

Phibro Animal Health Corporation

PAHC

28.01 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

4.45 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

51.17 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

10.35 USD

ImmunoGen, Inc. logo

ImmunoGen, Inc.

IMGN

31.235 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)